AN2 Therapeutics Rings the Nasdaq Stock Market Opening Bell

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. AN2 is developing epetraborole, a once-daily oral treatment for patients with NTM lung disease, a rare, chronic and progressive infectious disease caused by bacteria known as mycobacteria that leads to irreversible lung damage and can be fatal. For more information, visit www.an2therapeutics.com. In honor of its initial public offering, Eric Easom, Co-Founder, President and CEO rings the Opening Bell.